Advances in Economics, Management and Political Sciences
- The Open Access Proceedings Series for Conferences
Proceedings of the 7th International Conference on Economic Management and Green Development
Series Vol. 40 , 10 November 2023
Open
Access | Article
Risks Analysis and Development Prediction in Pharmaceutical Industry: A Case Study of Johnson and Johnson, Pfizer and Roche
* Author to whom correspondence should be addressed.
Abstract
Pharmaceutical innovations, including drugs and vaccines, consistently remain a top priority in development and research efforts. The COVID-19 pandemic has further emphasized the significance of drug research and development, prompting a growing number of nations to invest in this field. Governments have increased funding and introduced various incentive policies to stimulate innovation, bolstering the expansion of the pharmaceutical market. As a result, the pharmaceutical sector has evolved into a fundamental economic pillar, closely linked to economic growth, healthcare standards, and the overall well-being of the population. Consequently, economists and investors now pay greater attention to the industry than ever before. Despite the heightened focus on pharmaceuticals, the sector is not without its challenges, with numerous risks presenting obstacles for many companies. Identifying and understanding these risks, developing strategies to overcome them, and determining methods to maintain competitiveness and market share in the future is crucial for the continued success of these enterprises. This paper will focus on the WACC calculation to reckon the risks for Johnson and Johnson, Pfizer, and Roche as examples of pharmaceutical companies, put them down to contrast and predict the development. It shows that Johnson and Johnson owns the highest WACC, while Roche owns the lowest.
Keywords
pharmaceutical industry, innovative drugs, vaccines, COVID-19 pandemic
References
1. Rukesh Yadav, Sangam Shah, Santosh Chhetri (2022), ANCA-associated vasculitis following Johnson and Johnson COVID-19 vaccine, Annals of Medicine and Surgery, Volume 79, 104123, ISSN 2049-0801, https://doi.org/10.1016/j.amsu.2022.104123.
2. Jia, H., Jin, J.Y. and Lindsay, B. (2023), “Case analysis: Johnson & Johnson and the COVID-19 vaccine”, The CASE Journal, Vol. ahead-of-print No. ahead-of-print. https://doi.org/10.1108/TCJ-06-2021-0089
3. Chelsea R Thorn, Divya Sharma, Rodney Combs, Sonal Bhujbal, Jennifer Romine, Xiaolu Zheng, Khurram Sunasara, Advait Badkar (2022), The journey of a lifetime — development of Pfizer’s COVID-19 vaccine, Current Opinion in Biotechnology, Volume 78, 102803, ISSN 0958-1669, https://doi.org/10.1016/j.copbio.2022.102803.
4. Quiroz, K. (2016), “Pharmaceutical megamergers’ dependence on existing products: The case for R&D in the Pfizer-Allergan merger”, Strategic Direction, Vol. 32 No. 6, pp. 30-32. https://doi.org/10.1108/SD-03-2016-0041
5. Georg Wuitschik, Martin Olbrich, Stefan Hildbrand (2022), Roche’s approach to green metrics in drug development, Current Research in Green and Sustainable Chemistry, Volume 5, 100293, ISSN 2666-0865, https://doi.org/10.1016/j.crgsc.2022.100293.
6. Béraud, M., Drajac, C. and Thomas, M. (2021), “Talent management after an acquisition: a case study of Roche and Genentech”, Strategic HR Review, Vol. 20 No. 1, pp. 30-35. https://doi.org/10.1108/SHR-09-2020-0082
7. Demir, M. and Min, M. (2019), “Consistencies and discrepancies in corporate social responsibility reporting in the pharmaceutical industry”, Sustainability Accounting, Management and Policy Journal, Vol. 10 No. 2, pp. 333-364. https://doi.org/10.1108/SAMPJ-03-2018-0094
8. Liza, S.A., Chowdhury, N.R., Paul, S.K., Morshed, M., Morshed, S.M., Bhuiyan, M.A.T. and Rahim, M.A. (2022), “Barriers to achieving sustainability in pharmaceutical supply chains in the post-COVID-19 era”, International Journal of Emerging Markets, Vol. ahead-of-print No. ahead-of-print. https://doi.org/10.1108/IJOEM-11-2021-1680
9. Brass, Olivier and Grenier, Emmanuel (2023), Stability Prediction Methodology to Manage Vaccines and Pharmaceutical Products. https://ssrn.com/abstract=4406130
10. Sabat, K.C., Bhattacharyya, S.S. and Krishnamoorthy, B. (2022), “Circular economy in pharmaceutical industry through the lens of stimulus organism response theory”, European Business Review, Vol. 34 No. 6, pp. 936-964. https://doi.org/10.1108/EBR-02-2022-0037
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 7th International Conference on Economic Management and Green Development
- ISBN (Print)
- 978-1-83558-101-8
- ISBN (Online)
- 978-1-83558-102-5
- Published Date
- 10 November 2023
- Series
- Advances in Economics, Management and Political Sciences
- ISSN (Print)
- 2754-1169
- ISSN (Online)
- 2754-1177
- DOI
- 10.54254/2754-1169/40/20231996
- Copyright
- 10 November 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited